| Tumor glycolysis as a target for cancer therapy: progress and prospects S Ganapathy-Kanniappan, JFH Geschwind Molecular cancer 12, 1-11, 2013 | 1064 | 2013 |
| Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death S Ganapathy-Kanniappan, JFH Geschwind, R Kunjithapatham, M Buijs, ... Anticancer research 29 (12), 4909-4918, 2009 | 172 | 2009 |
| A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia MA McDevitt, J Xie, S Ganapathy-Kanniappan, J Griffith, A Liu, ... The Journal of experimental medicine 203 (5), 1185-1196, 2006 | 168 | 2006 |
| Molecular intricacies of aerobic glycolysis in cancer: current insights into the classic metabolic phenotype S Ganapathy-Kanniappan Critical Reviews in Biochemistry and Molecular Biology, 2019 | 166 | 2019 |
| 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy S Ganapathy-Kanniappan, M Vali, R Kunjithapatham, M Buijs, LH Syed, ... Current pharmaceutical biotechnology 11 (5), 510-517, 2010 | 148 | 2010 |
| Linking tumor glycolysis and immune evasion in cancer: emerging concepts and therapeutic opportunities S Ganapathy-Kanniappan Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1868 (1), 212-220, 2017 | 97 | 2017 |
| Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting S Ganapathy-Kanniappan, R Kunjithapatham, JF Geschwind Anticancer research 33 (1), 13-20, 2013 | 97 | 2013 |
| Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma S Ganapathy-Kanniappan, R Kunjithapatham, JF Geschwind Oncotarget 3 (9), 940, 2012 | 96 | 2012 |
| Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2 KE Elagib, M Xiao, IM Hussaini, LL Delehanty, LA Palmer, FK Racke, ... Molecular and cellular biology, 2004 | 86 | 2004 |
| 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines S Ganapathy-Kanniappan, JFH Geschwind, R Kunjithapatham, M Buijs, ... Anticancer research 30 (3), 923-935, 2010 | 72 | 2010 |
| Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer J Chapiro, S Sur, LJ Savic, S Ganapathy-Kanniappan, J Reyes, R Duran, ... Clinical Cancer Research 20 (24), 6406-6417, 2014 | 63 | 2014 |
| Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists S Ganapathy-Kanniappan, R Kunjithapatham, MS Torbenson, PP Rao, ... Radiology 262 (3), 834-845, 2012 | 53 | 2012 |
| Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study M Vali, JA Vossen, M Buijs, JM Engles, E Liapi, VP Ventura, A Khwaja, ... Journal of Pharmacology and Experimental Therapeutics 327 (1), 32-37, 2008 | 50 | 2008 |
| The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity S Ganapathy-Kanniappan, JFH Geschwind, R Kunjithapatham, M Buijs, ... Assay and drug development technologies 8 (2), 258-262, 2010 | 43 | 2010 |
| Spontaneous tumor regression in a syngeneic rat model of liver cancer: implications for survival studies M Buijs, JFH Geschwind, LH Syed, S Ganapathy-Kanniappan, ... Journal of Vascular and Interventional Radiology 23 (12), 1685-1691, 2012 | 42 | 2012 |
| Reversal of anchorage-independent multicellular spheroid into a monolayer mimics a metastatic model R Kunjithapatham, S Karthikeyan, JF Geschwind, E Kieserman, MD Lin, ... Scientific reports 4 (1), 6816, 2014 | 38 | 2014 |
| Taming tumor glycolysis and potential implications for immunotherapy S Ganapathy-Kanniappan Frontiers in oncology 7, 36, 2017 | 35 | 2017 |
| Evolution of GAPDH as a druggable target of tumor glycolysis? S Ganapathy-Kanniappan Expert opinion on therapeutic targets 22 (4), 295-298, 2018 | 34 | 2018 |
| Deregulation of energy metabolism promotes antifibrotic effects in human hepatic stellate cells and prevents liver fibrosis in a mouse model S Karthikeyan, JJ Potter, JF Geschwind, S Sur, JP Hamilton, B Vogelstein, ... Biochemical and biophysical research communications 469 (3), 463-469, 2016 | 33 | 2016 |
| Preclinical benefit of hypoxia-activated intra-arterial therapy with evofosfamide in liver cancer R Duran, S Mirpour, V Pekurovsky, S Ganapathy-Kanniappan, CF Brayton, ... Clinical Cancer Research 23 (2), 536-548, 2017 | 32 | 2017 |
